Puma Biotechnology hosted a conference call and provided a corporate update on May 7, 2026, following release of its 1Q-2026 ...

Preliminary response data for VIR-5818 (HER2-targeted) and VIR-5525 (EGFR-targeted) are expected in 2026 to inform dose ...

(Michael on for Roanna Ruiz), Leerink Partners: "what would constitute a clear signal as a green light to initiate Phase III in 2027?"; President, CEO & Director De Backer: "it's going to really be ...

Beneath the beauty of coral reefs lies a hidden universe of microbes unlike anything scientists expected. Each coral species ...

Odyssey Therapeutics Inc. raised $304 million in an upsized US initial public offering priced at the top of a marketed range, ...

(PBYI) on Thursday reported a loss of $3.8 million in its first quarter. The Los Angeles-based company said it had a loss of 7 cents ...

Virginia has invested in recent years to become a leader in biotechnology. This week, city and state leaders cut the ribbon ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

G&A expenses were $10.8 million for the first quarter of 2026, compared to $8.8 million for the first quarter of 2025. The increase was primarily due to an increase in compensation expense, including ...

Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and ...

A routine experiment with a new single-cell DNA sequencing method turned into a surprising scientific twist when researchers ...

The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.